Skip to main content
SpringerLink
Log in

Balsalazide: increasing the choice for patients with ulcerative colitis

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Farrokhyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001; 36(1): 2–15

    Article  PubMed  CAS  Google Scholar 

  2. Muijsers RBR, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs 2002; 62(11): 1689–705

    Article  PubMed  CAS  Google Scholar 

  3. Ardizzone S, Porro GB. Comparative tolerability of therapies for ulcerative colitis. Drug Safety 2002; 25(8): 561–82

    Article  PubMed  CAS  Google Scholar 

  4. Kornbluth A, Sachar DB. Ulcerative colitis practive guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92(2): 204–11

    PubMed  CAS  Google Scholar 

  5. British National Formulary No 44 [online]. Available from URL: http://www.bnf.org [Accessed 2003 May 5]

  6. Salix Pharmaceuticals. Colazal (balsalazide disodium) capsules: US full prescribing information [online]. Available from URL: http://www.colazal.com [Accessed 2003 May]

  7. Green JRB, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998; 114(1): 15–22

    Article  PubMed  CAS  Google Scholar 

  8. Levine DS, Riff DS, Pruitt R, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97(6): 1398–407

    PubMed  CAS  Google Scholar 

  9. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97(12): 3078–86

    Article  PubMed  CAS  Google Scholar 

  10. Mansfield JC, Giaffer MH, Cann PA, et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002; 16(1): 69–77

    Article  PubMed  CAS  Google Scholar 

  11. Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002; 16(1): 61–8

    Article  PubMed  CAS  Google Scholar 

  12. Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998; 12(12): 1207–16

    Article  PubMed  CAS  Google Scholar 

  13. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001; 49(6): 783–9

    Article  PubMed  CAS  Google Scholar 

  14. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988; 2(3): 237–43

    Article  PubMed  CAS  Google Scholar 

  15. Green JR, Swan CH, Rowlinson A, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992; 6(5): 647–52

    Article  PubMed  CAS  Google Scholar 

  16. Giaffer MH, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 1992; 6(4): 479–85

    Article  PubMed  CAS  Google Scholar 

  17. Shire Pharmaceuticals Limited. Colazide (balsalazide disodium): UK full prescribing information [online]. Available from URL: http://emc.vhn.net [Accessed 2002 Mar 18]

  18. Giaffer MH, O’Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992; 6(1): 51–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balsalazide: increasing the choice for patients with ulcerative colitis. Drugs Ther. Perspect 19, 1–4 (2003). https://doi.org/10.2165/00042310-200319100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319100-00001

Keywords

Search

Navigation